China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based Baiyiyuan Biotech, securing exclusive rights to promote, market, and commercialize Baiyiyuan’s decellularized matrix implant across Greater China, including the China mainland, Hong Kong, Macau, and Taiwan. The financial details of the agreement were not disclosed.
The Category III medical device, a collagen-based product infused with bioactive ingredients, is designed for mid to deep dermal facial injections to address nasolabial folds and wrinkles. It is currently in the regulatory clinical stage. Pre-clinical studies indicate that the product and its degradation products are safe, showing no adverse effects on the local implanted area or the systemic system. The product has demonstrated promising potential for filling and regenerative effects.- Flcube.com
